Warren Buffett, one of the most successful dividend investors in history, owes much of his financial success to a simple yet powerful strategy: dividend reinvestment programs (DRIP). This approach leverages the power of compounding by reinvesting dividend earnings back into the stock, creating a snowball effect that can significantly grow an investment over time.
Long-term dividend investors can take advantage of the DRIP strategy to build substantial wealth, and Johnson & Johnson JNJ is a prime candidate for those looking to become dividend millionaires in about ten years.
Trending: New fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends get started today for just $100.
Why Johnson & Johnson?
Johnson & Johnson, a global healthcare giant, has a long-standing reputation for stability, consistent dividend payments, and a robust business model. Despite challenges, such as recent legal battles and the spin-off of its consumer health division, the company remains a solid choice for dividend investors due to its diversified revenue streams across pharmaceuticals, medical devices, and consumer health products.
The company has a history of rewarding shareholders, with a dividend yield of approximately 2.85% and a five-year dividend growth rate of 6.04%. This steady dividend growth, coupled with its resilient stock price, makes J&J an attractive option for those looking to leverage the power of compounding dividends.
Projected Growth Over 10 Years
As the table below demonstrates, an initial investment of $50,000 in Johnson & Johnson, with monthly top-ups of $500 ($6,000 per year), won’t fully take you to $1 million by 2034. However, it will get you over halfway there, assuming the stock maintains its current annual dividend growth rate of 6.04% and a projected stock price growth rate of 8% per year. The stock and dividend yield could fluctuate over time; this is just a rough estimate.
| Year | Shares Owned | Starting Stock Price | Year-End Dividend After Taxes | Final Balance After Taxes |
| 2024 | 261 | $192.44 | $1,321.90 | $52,000 |
| 2025 | 288 | $207.84 | $1,568.32 | $69,635 |
| 2026 | 318 | $224.47 | $1,868.83 | $91,102 |
| 2027 | 351 | $242.43 | $2,230.64 | $117,208 |
| 2028 | 387 | $261.82 | $2,661.54 | $149,036 |
| 2029 | 426 | $282.75 | $3,170.67 | $187,960 |
| 2030 | 469 | $305.32 | $3,768.40 | $235,750 |
| 2031 | 516 | $329.66 | $4,466.36 | $294,599 |
| 2032 | 566 | $355.91 | $5,277.32 | $367,247 |
| 2033 | 621 | $384.23 | $6,215.10 | $457,035 |
| 2034 | 681 | $414.76 | $7,294.72 | $567,969 |
Don't Miss Out: Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class. Get started investing in commercial real estate today.
Recent Performance and Outlook
Johnson & Johnson’s stock has seen stable performance, with recent gains driven by strong earnings reports and the company’s strategic focus on high-growth areas such as oncology and immunology. The separation of its consumer health division, Kenvue, has allowed J&J to concentrate on its core businesses, potentially leading to better long-term growth prospects.
Institutional investors are also showing confidence in Johnson & Johnson. In the first half of 2024, Vanguard increased its holdings by 2.5 million shares, while BlackRock added 1.8 million shares, signaling strong institutional support for the company's future growth.
Analysts remain optimistic about Johnson & Johnson’s future, with several upgrading their price targets following the Kenvue spin-off. The company’s robust pipeline of new drugs, particularly in the oncology sector, is expected to drive revenue growth. Additionally, J&J’s ongoing legal resolutions are likely to remove some uncertainty, further stabilizing the stock.
Diversifying with High-Yield Alternatives
While Johnson & Johnson offers a solid path to building wealth through dividends, investors should also consider diversifying their portfolios with high-yield alternatives. Two options worth exploring are the Ascent Income Fund and the Arrived Private Credit Fund.
The Ascent Income Fund targets stable income from senior commercial real estate debt positions, offering a historical distribution yield of 10.38% backed by real assets. This fund provides a strong complement to dividend investing by offering payment priority and flexible liquidity options.
Similarly, the Arrived Private Credit Fund simplifies investing in short-term financing for real estate projects, providing attractive yields secured by quality residential real estate. With target annualized dividends of 7-9%, this fund is an excellent way to balance risk and reward in a diversified investment strategy.
By investing in Johnson & Johnson and leveraging dividend compounding, along with exploring high-yield alternatives like the Ascent Income Fund and Arrived Private Credit Fund, investors can create a resilient, income-generating portfolio capable of weathering various market conditions. This approach can pave the way to becoming a dividend millionaire within the next decade.
Disclosure: This story was previously published on Benzinga and has been updated.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
